Home/Pipeline/LR19129

LR19129

Solid Tumor

Pre-clinicalActive

Key Facts

Indication

Solid Tumor

Phase

Pre-clinical

Status

Active

Company

AVEO Oncology

About AVEO Oncology

AVEO Oncology is a clinical-stage biopharmaceutical company specializing in targeted cancer therapies, operating as a U.S. subsidiary of South Korea's LG Chem. The company has one FDA-approved product, FOTIVDA for renal cell carcinoma, and a diverse early-to-mid-stage pipeline focused on monoclonal antibodies and novel mechanisms. Its business model centers on in-licensing, co-development, and commercialization, aiming to grow into a global oncology leader by leveraging LG Chem's resources and strategic partnerships.

View full company profile

Therapeutic Areas

Oncology Supportive Care (Cancer Cachexia)

Other Solid Tumor Drugs

Drug	Company	Phase	Status
AV-203	AVEO Oncology	Pre-clinical	Active
LR19155	AVEO Oncology	Pre-clinical	Active
LR20011	AVEO Oncology	Pre-clinical	Active
LR19023	AVEO Oncology	Pre-clinical	Active
Undisclosed Transcription Factor	Talus Bioscience	Discovery	Active
RGI-AB-01	REGiMMUNE	Preclinical	Active
RGI-AB-02	REGiMMUNE	Preclinical	Active
RGI-AB-03	REGiMMUNE	Preclinical	Active
RGI-AB-04	REGiMMUNE	Preclinical	Active
CS028	Lumosa Therapeutics	Pre‑clinical	Active